Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      

GlaxoSmithKline Unit Takes 25.4% Stake In Autifony Therqapeu


45427 akademikeren 22/8 2011 10:07
Oversigt

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN), the drug giant, Monday announced that its wholly-owned subsidiary Glaxo Group Limited, or GSK, will receive a 25.4% minority equity stake, representing a GBP1,250,000 investment, in Autifony Therapeutics Limited, a U.K.-based biotechnology start up created through a funding round of up to GBP10 million alongside investors Imperial Innovations and SV Life Sciences.

MAIN FACTS:

-Under the terms of the agreement, Autifony will issue 850,000 A ordinary shares to GSK in exchange for a number of pre-candidate voltage-gated ion channel modulator compounds and associated patent applications and data for development in hearing loss, as well as 571,429 Series A preferred shares in recognition of GBP400,000 worth of development work funded by GSK on behalf of Autifony.

-GSK will also be eligible to receive a further 550,000 A ordinary shares on achievement of a pre-determined milestone, at which time there will be a further investment by the existing consortium and GSK will then own 13.2% of Autifony on a fully diluted basis.

-GlaxoSmithKline PLC shares closed Friday at GBP12.43 valuing the company at GBP63.22 billion.



TRÅDOVERSIGT